NCT05559554 - A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

October 25, 2022

Primary Completion Date

March 24, 2023

Study Completion Date

April 6, 2023

Conditions

Healthy Male Subjects

Interventions

DRUG

AK104 (before the change)

Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.

DRUG

AK104 (after the change)

Dose 1 and dose 2 in pilot study, and recommended dose in pivotal study.

Trial Locations (1)

The Third Hospital of Changsha, Changsha